AE
AEON.US AEON Biopharma, Inc.
- Market cap
- USD 12.0M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AEON.US undervalued?
Graham numberThe Graham number of AEON Biopharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AEON Biopharma, Inc. fundamental analysis
No fundamental analysis for AEON Biopharma, Inc. yet.
AEON Biopharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements …
Full company profileAEON Biopharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AEON Biopharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3.36M | 2.52M | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.36M | 2.52M | - | - | - | - | -78.0K | -78.0K |
| Operating Income | -54.0M | -16.4M | -65.8M | -48.4M | -348M | 73.0M | -12.8M | -23.7M |
| EBITDA | -47.1M | -15.5M | -36.9M | -52.5M | -52.7M | -27.7M | -16.2M | -35.4M |
| Net Income | 173M | -32.9M | -55.6M | -52.6M | -385M | 42.0M | -39.2M | -25.9M |
| EPS | 1,873 | -69 | -128 | -27 | -745 | 73 | -3.95 | -0.51 |
| Balance Sheet | ||||||||
| Total Assets | 114M | 21.2M | 6.44M | 10.8M | 6.85M | 3.14M | 5.56M | 5.91M |
| Total Liabilities | 180M | 224M | 230M | 281M | 160M | 31.7M | 60.6M | 21.3M |
| Shareholders' Equity | -67.2M | -208M | -235M | -288M | -153M | -28.6M | -55.0M | -15.4M |
| Cash & Short-term Investments | 112M | 20.2M | 5.13M | 9.75M | 5.16M | 13.0K | 3.01M | 3.43M |
| Total Debt | 30.0M | 72.2M | 86.9M | 132M | 278K | 13.0M | 35.7M | 2.78M |
| Cash Flow | ||||||||
| Operating Cash Flow | -44.7M | -9.46M | -28.4M | -35.6M | -47.8M | -20.3M | -17.3M | -12.7M |
| Capital Expenditure | 1.69M | 170K | 170K | 306K | 0.00 | 0.00 | 4.00K | 0.00 |
| Free Cash Flow | -46.4M | -9.46M | -28.6M | -35.9M | -47.8M | -20.3M | -17.3M | -12.7M |
| Ratios | ||||||||
| ROA | 151.2% | -155.1% | -864.5% | -487.6% | -5,619.2% | 1,336.9% | -705.4% | -438.2% |
| Net Profit Margin | 5,151.0% | -1,307.1% | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AEON Biopharma, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 83.9M | 909 | 48.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:72 on Feb 26, 2025.
Who owns AEON Biopharma, Inc.
- Insiders 54.32%
- Institutions 14.32%
- Public & others 31.36%
- Shares outstanding 71.5M
- Free float 12.5M
AEON Biopharma, Inc. company profile
- Company name
- AEON Biopharma, Inc.
- Ticker
- AEON.US
- Exchange
- USA Stocks
- Listed since
- Apr 12, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 5 Park Plaza, Irvine, CA, United States, 92614
- Phone
- 949 354 6499
- Website
- aeonbiopharma.com
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
AEON Biopharma, Inc. management
6- Mr. Robert BancroftPresident, CEO & Director · born 1965
- Mr. Alex WilsonChief Legal & Strategy Officer and Corporate Secretary · born 1986
- Dr. Chad K. Oh M.D.Chief Medical Officer · born 1958
- Mr. John A. Bencich M.B.A.Chief Financial Officer · born 1977
- Ms. Jennifer SyChief Accounting Officer · born 1985
- Dr. Paul Lee M.D., Ph.D.Chief Regulatory Officer